Mitchell Diccianni

TitleProject Scientist
InstitutionUniversity of California San Diego
Address200 W. Arbor Drive #8447
San Diego CA 92103
vCardDownload vCard

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Ozkaynak MF, Gilman AL, London WB, Naranjo A, Diccianni M, Tenney SC, Smith M, Messer KS, Seeger R, Reynolds CP, Smith LM, Shulkin BL, Parisi M, Maris JM, Park JR, Sondel PM, Yu AL. A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children's Oncology Group Study ANBL0931. Front Immunol. 2018; 9:1355. PMID: 29967609.
      View in: PubMed
    2. Erbe AK, Wang W, Carmichael L, Kim K, Mendonça EA, Song Y, Hess D, Reville PK, London WB, Naranjo A, Hank JA, Diccianni M, Reisfeld RA, Gillies SD, Matthay KK, Cohn SL, Hogarty MD, Maris JM, Park JR, Ozkaynak MF, Gilman AL, Yu AL, Sondel PM. Neuroblastoma Patients' KIR and KIR-Ligand Genotypes Influence Clinical Outcome for Dinutuximab-based Immunotherapy: A Report from the Children's Oncology Group. Clin Cancer Res. 2018 Jan 01; 24(1):189-196. PMID: 28972044.
      View in: PubMed
    3. Mody R, Naranjo A, Van Ryn C, Yu AL, London WB, Shulkin BL, Parisi MT, Servaes SE, Diccianni M, Sondel PM, Bender JG, Maris JM, Park JR, Bagatell R. Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial. Lancet Oncol. 2017 Jul; 18(7):946-957. PMID: 28549783.
      View in: PubMed
    4. Batova A, Altomare D, Creek KE, Naviaux RK, Wang L, Li K, Green E, Williams R, Naviaux JC, Diccianni M, Yu AL. Englerin A induces an acute inflammatory response and reveals lipid metabolism and ER stress as targetable vulnerabilities in renal cell carcinoma. PLoS One. 2017; 12(3):e0172632. PMID: 28296891.
      View in: PubMed
    5. Williams RT, Yu AL, Diccianni M, Theodorakis EA, Batova A. Erratum: renal cancer-selective Englerin A induces multiple mechanisms of cell death and autophagy. J Exp Clin Cancer Res. 2014 Dec 05; 33:95. PMID: 25480670; PMCID: PMC4272799.
    6. Barnhill LM, Williams RT, Cohen O, Kim Y, Batova A, Mielke JA, Messer K, Pu M, Bao L, Yu AL, Diccianni M. High expression of CAI2, a 9p21-embedded long noncoding RNA, contributes to advanced-stage neuroblastoma. Cancer Res. 2014 Jul 15; 74(14):3753-63. PMID: 25028366; PMCID: PMC4126165.
    7. Terme M, Dorvillius M, Cochonneau D, Chaumette T, Xiao W, Diccianni M, Barbet J, Yu AL, Paris F, Sorkin LS, Birklé S. Chimeric antibody c.8B6 to O-acetyl-GD2 mediates the same efficient anti-neuroblastoma effects as therapeutic ch14.18 antibody to GD2 without antibody induced allodynia. PLoS One. 2014; 9(2):e87210. PMID: 24520328; PMCID: PMC3919714.
    8. Williams RT, Barnhill LM, Kuo HH, Lin WD, Batova A, Yu AL, Diccianni M. Chimeras of p14ARF and p16: functional hybrids with the ability to arrest growth. PLoS One. 2014; 9(2):e88219. PMID: 24505435; PMCID: PMC3914946.
    9. Kelner MJ, Diccianni M, Yu AL, Rutherford MR, Estes LA, Morgenstern R. Absence of MGST1 mRNA and protein expression in human neuroblastoma cell lines and primary tissue. Free Radic Biol Med. 2014 Apr; 69:167-71. PMID: 24486338; PMCID: PMC4010302.
    10. Williams RT, Yu AL, Diccianni M, Theodorakis EA, Batova A. Renal cancer-selective Englerin A induces multiple mechanisms of cell death and autophagy. J Exp Clin Cancer Res. 2013 Aug 20; 32:57. PMID: 23958461; PMCID: PMC3765946.
    11. Lin RJ, Lin YC, Chen J, Kuo HH, Chen YY, Diccianni M, London WB, Chang CH, Yu AL. microRNA signature and expression of Dicer and Drosha can predict prognosis and delineate risk groups in neuroblastoma. Cancer Res. 2010 Oct 15; 70(20):7841-50. PMID: 20805302; PMCID: PMC4095771.
    12. Lo TC, Barnhill LM, Kim Y, Nakae EA, Yu AL, Diccianni M. Inactivation of SHIP1 in T-cell acute lymphoblastic leukemia due to mutation and extensive alternative splicing. Leuk Res. 2009 Nov; 33(11):1562-6. PMID: 19473701; PMCID: PMC2735879.
    13. Yang HC, Huang MC, Li LH, Lin CH, Yu AL, Diccianni M, Wu JY, Chen YT, Fann CS. MPDA: microarray pooled DNA analyzer. BMC Bioinformatics. 2008 Apr 15; 9:196. PMID: 18412951; PMCID: PMC2387178.
    14. Batova A, Cottam H, Yu J, Diccianni M, Carrera CJ, Yu AL. EFA (9-beta-D-erythrofuranosyladenine) is an effective salvage agent for methylthioadenosine phosphorylase-selective therapy of T-cell acute lymphoblastic leukemia with L-alanosine. Blood. 2006 Feb 01; 107(3):898-903. PMID: 16234352; PMCID: PMC1895892.
    15. Gebauer S, Yu AL, Omura-Minamisawa M, Batova A, Diccianni M. Expression profiles and clinical relationships of ID2, CDKN1B, and CDKN2A in primary neuroblastoma. Genes Chromosomes Cancer. 2004 Dec; 41(4):297-308. PMID: 15390183.
      View in: PubMed
    16. Diccianni M, Yu J, Meppelink G, de Vries M, Shao L, Gebauer S, Shih H, Roberts W, Kilcoin NP, Pullen J, Carson DA, Yu AL. 3-amino thioacridone inhibits DNA synthesis and induce DNA damage in T-cell acute lymphoblastic leukemia (T-ALL) in a p16-dependent manner. J Exp Ther Oncol. 2004 Oct; 4(3):223-37. PMID: 15724842.
      View in: PubMed
    17. Batova A, Shao LE, Diccianni M, Yu AL, Tanaka T, Rephaeli A, Nudelman A, Yu J. The histone deacetylase inhibitor AN-9 has selective toxicity to acute leukemia and drug-resistant primary leukemia and cancer cell lines. Blood. 2002 Nov 01; 100(9):3319-24. PMID: 12384433.
      View in: PubMed
    18. Broome HE, Yu AL, Diccianni M, Camitta BM, Monia BP, Dean NM. Inhibition of Bcl-xL expression sensitizes T-cell acute lymphoblastic leukemia cells to chemotherapeutic drugs. Leuk Res. 2002 Mar; 26(3):311-6. PMID: 11792421.
      View in: PubMed